WASHINGTON (Reuters) – Pfizer Inc and BioNTech said on Thursday they had asked U.S. regulators to approve emergency use of their COVID-19 vaccine for children aged from five to 11, Pfizer said in a post on Twitter.
“We and @BioNTech_Group officially submitted our request to
@US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12," the company said.
(Reporting by Susan Heavey, Editing by Timothy Heritage)
